Does the Benefit of Thrombectomy in Large Strokes Depend on Perfusion-Diffusion Mismatch? A Large Stroke Therapy Evaluation Trial Post Hoc Analysis


Por: Ter Schiphorst, A, Arquizan, C, Turc, G, Labreuche, J, Lapergue, B, Liebeskind, DS, Henon, H, Nouri, N, Albucher, JF, Cognard, C, Marnat, G, Sibon, I, Gory, B, Richard, S, Naggara, O, Annan, M, Boulouis, G, Omer, EF, Cho, TH, Di Maria, F, Bourcier, R, Guillon, B, Obadia, M, Piotin, M, Ferrier, A, Chabert, E, Millán, M, van Dokkum, L, Jovin, TG, Le Bars, E and Costalat, V

Publicada: 1 ene 2026
Resumen:
Background and Purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large Stroke Therapy Evaluation (LASTE) randomized controlled trial (RCT). Methods The LASTE RCT compared MT plus best medical treatment (BMT) to BMT alone in patients with large infarct (Alberta Stroke Program Early CT Score 0-5) in the 0-7-hour time-window. This secondary analysis was restricted to patients with available baseline MR perfusion-weighted imaging. We investigated the potential heterogeneity of MT treatment according to the presence of perfusion-diffusion mismatch, defined as a mismatch ratio >= 1.2, calculated as the time-to-maximum >6 seconds cerebral volume divided by ischemic core volume. The primary outcome was better functional outcome (favorable shift in the distribution of modified Rankin Scale [mRS] at 90 days, analyzed using generalized odds ratio [GenOR]). Results A total of 102/324 patients were included, among whom 55 (54%) had a perfusion-diffusion mismatch. No significant treatment effect heterogeneity by diffusion-perfusion mismatch was observed for the primary outcome (GenOR for better functional outcome: 1.70 [95% confidence interval, CI, 0.95 to 3.05] and 1.04 [95% CI, 0.57 to 1.87] in patients with and without mismatch, respectively; ratio of GenORs: 1.63 [95% CI, 0.71 to 3.74]; P for heterogeneity=0.24) or for the secondary efficacy and safety outcomes. Conclusions Our study found no evidence of heterogeneity of treatment effect with respect to benefit or safety in patients with unrestricted infarct size at baseline treated with MT by presence of perfusion-diffusion mismatch. An individual participant-data meta-analysis of RCT is needed for definitive conclusions.

Filiaciones:
Ter Schiphorst, A:
 CHRU Gui de Chauliac, Dept Neurol, Montpellier, France

 Univ Montpellier, Inst Genom Fonct, CNRS, INSERM, Montpellier, France

 Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France

Arquizan, C:
 CHRU Gui de Chauliac, Dept Neurol, Montpellier, France

 Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France

Turc, G:
 Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France

 Hop St Anne, Dept Neurol, GHU Paris Psychiat & Neurosci, Paris, France

Labreuche, J:
 Ctr Hosp Univ CHU Lille, Dept Biostat, Lille, France

Lapergue, B:
 Versailles St Quentin En Yvelines Univ, Foch Hosp, Dept Neurol, Suresnes, France

Liebeskind, DS:
 Univ Calif Los Angeles, UCLA Comprehens Stroke Ctr, Dept Neurol, Los Angeles, CA USA

Henon, H:
 Ctr Hosp Univ CHU Lille, Dept Neurol, Lille, France

Nouri, N:
 Ctr Hosp Univ CHU Lille, Dept Neuroradiol, Lille, France

Albucher, JF:
 Hop Pierre Paul Riquet, Dept Neurol, Toulouse, France

 Toulouse Clin Invest Ctr 1436, Toulouse, France

Cognard, C:
 Toulouse Clin Invest Ctr 1436, Toulouse, France

 Hop Pierre Paul Riquet, Dept Neuroradiol, Toulouse, France

Marnat, G:
 Hop Pellegrin, Dept Neuroradiol, Bordeaux, France

Sibon, I:
 Hop Pellegrin, Dept Neurol, Bordeaux, France

Gory, B:
 Univ Lorraine, Dept Diagnost & Therapeut Neuroradiol, CHRU Nancy, Nancy, France

 Univ Lorraine, CHRU Nancy, INSERM, CIC,U1254,Innovat Technol, Nancy, France

Richard, S:
 Hop Cent, Dept Neurol, Nancy, France

 INSERM, Ctr Invest Clin Plurithemat 1433, Nancy, France

Naggara, O:
 Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France

 Hop St Anne, Dept Neuroradiol, GHU Paris Psychiat & Neurosci, Paris, France

Annan, M:
 Hop Bretonneau, Dept Neurol, Tours, France

Boulouis, G:
 Hop Bretonneau, Dept Neuroradiol, Tours, France

Omer, EF:
 Hop Pierre Wertheimer, Dept Neuroradiol, Hosp Civils Lyon, Grp Hosp Est, Lyon, France

Cho, TH:
 Hop Pierre Wertheimer, Dept Neurol, Hosp Civils Lyon, Grp Hosp Est, Lyon, France

Di Maria, F:
 Versailles St Quentin En Yvelines Univ, Foch Hosp, Dept Neuroradiol, Suresnes, France

Bourcier, R:
 Nantes Univ, Dept Neuroradiol, CHU Nantes, Nantes, France

 Univ Nantes, Inst Thorax, Ctr Natl Rech Sci, INSERM Un Mixte Rech 1087, Nantes, France

Guillon, B:
 CHU Nantes, Dept Neurol, Hop GR Laennec, Nantes, France

Obadia, M:
 Hop Fdn Adolphe de Rothschild, Dept Neurol, Paris, France

Piotin, M:
 Hop Fdn Adolphe de Rothschild, Dept Interventionnal Neuroradiol, Paris, France

Ferrier, A:
 CHU Clermont Ferrand, Hop Gabriel Montpied, Dept Neurol, Clermont Ferrand, France

Chabert, E:
 CHU Clermont Ferrand, Hop Gabriel Montpied, Dept Neuroradiol, Clermont Ferrand, France

:
 Hosp Germans Trias i Pujol, Dept Neurol, Badalona, Spain

Jovin, TG:
 Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Neurol, Camden, NJ USA

Le Bars, E:
 CHRU Gui de Chauliac, Dept Neuroradiol, Montpellier, France

 Univ Montpellier, CNRS, L2C, Montpellier, France

Costalat, V:
 Univ Montpellier, Inst Genom Fonct, CNRS, INSERM, Montpellier, France

 CHRU Gui de Chauliac, Dept Neuroradiol, Montpellier, France
ISSN: 22876391





Journal of Stroke
Editorial
Korean Stroke Society, C/O CHIN-SANG CHUNG, DEPT NEUROL, SAMSUNG MED CTR, SUNGKYUNKWAN UNIV, SCH MED, IRWON-RO, GANGNAM-GU, SEOUL, 135-710, SOUTH KOREA
Tipo de documento: Article
Volumen: 28 Número: 1
Páginas:
WOS Id: 001692449400007
ID de PubMed: 41656636
imagen Green Submitted, gold

MÉTRICAS